- Home
- CUE vs PETS Comparison
CUE vs PETS Comparison
Compare CUE & PETS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- PETS
- Stock Information
- Founded
- CUE 2014
- PETS 1996
- Country
- CUE United States
- PETS United States
- Employees
- CUE N/A
- PETS N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- PETS Retail-Drug Stores and Proprietary Stores
- Sector
- CUE Health Care
- PETS Consumer Staples
- Exchange
- CUE Nasdaq
- PETS Nasdaq
- Market Cap
- CUE 56.1M
- PETS 53.7M
- IPO Year
- CUE 2018
- PETS N/A
- Fundamental
- Price
- CUE $0.86
- PETS $2.56
- Analyst Decision
- CUE Strong Buy
- PETS Sell
- Analyst Count
- CUE 2
- PETS 1
- Target Price
- CUE $3.00
- PETS $3.20
- AVG Volume (30 Days)
- CUE 220.6K
- PETS 108.2K
- Earning Date
- CUE 11-13-2025
- PETS 11-05-2025
- Dividend Yield
- CUE N/A
- PETS N/A
- EPS Growth
- CUE N/A
- PETS N/A
- EPS
- CUE N/A
- PETS 0.02
- Revenue
- CUE $8,286,000.00
- PETS $247,010,000.00
- Revenue This Year
- CUE N/A
- PETS N/A
- Revenue Next Year
- CUE N/A
- PETS N/A
- P/E Ratio
- CUE N/A
- PETS $150.61
- Revenue Growth
- CUE N/A
- PETS N/A
- 52 Week Low
- CUE $0.54
- PETS $2.45
- 52 Week High
- CUE $1.99
- PETS $6.85
- Technical
- Relative Strength Index (RSI)
- CUE 58.69
- PETS 37.62
- Support Level
- CUE $0.71
- PETS $2.52
- Resistance Level
- CUE $0.73
- PETS $2.64
- Average True Range (ATR)
- CUE 0.04
- PETS 0.08
- MACD
- CUE 0.01
- PETS 0.01
- Stochastic Oscillator
- CUE 95.92
- PETS 27.78
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.